Cancer - STAT

Health By Elizabeth Cooney

When Covid first hit, prostate cancer surgeries fell much more for Black men than white men

Health By Theresa Gaffney

Death rates are declining for many common cancers in the U.S., report finds

Adam's Take By Adam Feuerstein

The failure of a cancer drug study leaves Cel-Sci on the brink of collapse

Pharmalot By Ed Silverman

U.S. cancer drug prices were higher at launch than in three European countries — and just kept climbing

The Readout LOUD By Damian Garde, Meg Tirrell, and Adam Feuerstein

Listen: FDA inner workings, GSK’s foggy future, & the alarming rise in colorectal cancer

Biotech By Adam Feuerstein

Arcus’ anti-TIGIT immunotherapy shows ‘encouraging’ tumor response, but likely leaves investors wanting more

Health By Kevin Lin

What the cancer research community can learn from the Covid-19 response

In the Lab By Megan Molteni

Scientists unshelve a decades-old antibiotic to fight a new foe — ovarian cancer

In the Lab By Emily Mullin

Scientists CRISPR patients’ own immune cells in bid to shrink hard-to-treat GI tumors

Health By Kevin Lin

Why two scientific powerhouses are teaming up to tackle rare cancers long overlooked in research

Biotech By Adam Feuerstein

GSK pays up big for rights to TIGIT-targeted cancer immunotherapy from Iteos

First Opinion By Cynthia A. Stuenkel and JoAnn E. Manson

Are five decades of progress in women’s health in peril?

Biotech By Matthew Herper

In potential big step forward for CAR-T, Bristol Myers says its therapy outperformed stem cell transplant in blood cancer

Biotech By Adam Feuerstein

Virtual Event: The ASCO Recap, Live!

Biotech By Kate Sheridan

Will you accept this capital investment? Biotech and health startups bet on a strange new reality show for crowdfunding

Pharma By Adam Feuerstein

Radioactive drug helps men with advanced prostate cancer, but survival benefit is debated

Biotech By Adam Feuerstein

Fate Therapeutics’ natural killer cells induce responses in blood cancer patients, but for how long?

Pharma By Adam Feuerstein

For first time, immunotherapy after surgery shows benefit for patients with early kidney cancer

Health By Matthew Herper

AstraZeneca drug prevents breast cancer caused by BRCA mutations from returning

Biotech By Adam Feuerstein

Amgen wins FDA approval for first KRAS-blocking lung cancer drug

Health By Elizabeth Cooney

‘We shouldn’t leave anybody behind’: Inequities in cancer genomics undercut promise of precision medicine

Exclusive By Megan Molteni and Katie Palmer

From two unusual organ donations, scientists garner a unique trove of single-cell genetic data

Health By Nicholas St. Fleur

STAT+ Conversations: A discussion on health disparities in colorectal cancer with Dr. Fola May

Biotech By Adam Feuerstein

Allogene’s blood cancer data show durability of off-the-shelf CAR-T cells

Pharma By Adam Feuerstein

Most Read

Chadwick Boseman’s tragedy is America’s tragedy: In colorectal cancer hot spots, young men are dying at higher rates

23andMe had devastating news about my health. I wish a person had delivered it

Will Gilead’s early data for its CAR-T therapy give it an edge over Bristol Myers?

Lavishly funded Moderna hits safety problems in bold bid to revolutionize medicine

How nanotechnology helps mRNA Covid-19 vaccines work

Peter Bach, industry critic, joins company aiming to make blood tests to detect cancer

Watch: An unusual 30th birthday gift: Why I got a colonoscopy so young — and documented every step

Key science officials detail their plans for a new research agency — and Congress is getting closer to funding it

All Coverage

When Covid first hit, prostate cancer surgeries fell much more for Black men than white men

Death rates are declining for many common cancers in the U.S., report finds

The failure of a cancer drug study leaves Cel-Sci on the brink of collapse

U.S. cancer drug prices were higher at launch than in three European countries — and just kept climbing

Listen: FDA inner workings, GSK’s foggy future, & the alarming rise in colorectal cancer

Arcus’ anti-TIGIT immunotherapy shows ‘encouraging’ tumor response, but likely leaves investors wanting more

What the cancer research community can learn from the Covid-19 response

Scientists unshelve a decades-old antibiotic to fight a new foe — ovarian cancer

Scientists CRISPR patients’ own immune cells in bid to shrink hard-to-treat GI tumors

Why two scientific powerhouses are teaming up to tackle rare cancers long overlooked in research

GSK pays up big for rights to TIGIT-targeted cancer immunotherapy from Iteos

Are five decades of progress in women’s health in peril?

In potential big step forward for CAR-T, Bristol Myers says its therapy outperformed stem cell transplant in blood cancer

Virtual Event: The ASCO Recap, Live!

Will you accept this capital investment? Biotech and health startups bet on a strange new reality show for crowdfunding

Radioactive drug helps men with advanced prostate cancer, but survival benefit is debated

Fate Therapeutics’ natural killer cells induce responses in blood cancer patients, but for how long?

For first time, immunotherapy after surgery shows benefit for patients with early kidney cancer

AstraZeneca drug prevents breast cancer caused by BRCA mutations from returning

Amgen wins FDA approval for first KRAS-blocking lung cancer drug

‘We shouldn’t leave anybody behind’: Inequities in cancer genomics undercut promise of precision medicine

From two unusual organ donations, scientists garner a unique trove of single-cell genetic data

STAT+ Conversations: A discussion on health disparities in colorectal cancer with Dr. Fola May

Allogene’s blood cancer data show durability of off-the-shelf CAR-T cells

With new data, J&J’s CAR-T drug benefits myeloma patients with less advanced disease